Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Director departure
GW PHARMACEUTICALS PLC (GWPH) Create: Alert

All | News | Filings
Date FiledTypeDescription
05/05/2021 8-K Quarterly results
04/23/2021 8-K Quarterly results
04/20/2021 8-K Quarterly results
04/14/2021 8-K Quarterly results
03/23/2021 8-K Quarterly results
02/16/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
02/03/2021 8-K Quarterly results
01/12/2021 8-K Quarterly results
11/03/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress",
"GW Pharmaceuticals Initiates Pivotal Phase 3 Study of Nabiximols for Multiple Sclerosis-Associated Spasticity"
09/10/2020 8-K Quarterly results
08/06/2020 8-K Quarterly results
05/27/2020 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
05/11/2020 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress"
02/25/2020 8-K Quarterly results
02/03/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals and Greenwich Biosciences Submit Supplemental New Drug Application to U.S. FDA for Epidiolex ® for the Treatment of Tuberous Sclerosis Complex London, UK, Carlsbad, CA, Feb 3, 2020 — GW Pharmaceuticals plc , the world leader in the science, development, and commercialization of cannabinoid prescription medicines, along with its U.S. subsidiary Greenwich Biosciences, Inc., announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for Epidiolex ® oral solution, CV. The sNDA seeks to expand the Epidiolex label to include the treatment of seizures associated with Tuberous Sclerosis Complex , a rare genetic condition. Epidiolex is currently approved in the U.S. to treat seizures associated with Lennox-Gastaut syndrome o..."
01/13/2020 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals Pre-Announces Preliminary Unaudited Fourth Quarter and Full-Year 2019 Net Product Sales"
11/05/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the Third Quarter Ended September 30, 2019"
09/23/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"GW Pharmaceuticals receives European Commission approval for EPIDYOLEX ® for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy"
08/06/2019 8-K Quarterly results
07/26/2019 8-K Other Events, Financial Statements and Exhibits
Docs: "GW Pharmaceuticals receives positive CHMP opinion for EPIDYOLEX™ for the treatment of seizures in patients with two rare, severe forms of childhood-onset epilepsy"
06/13/2019 8-K Submission of Matters to a Vote of Security Holders
06/13/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Presentation at the Annual General Meeting on June 13, 2019"
05/06/2019 8-K Quarterly results
Docs: "GW Pharmaceuticals plc Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2019",
"GW Pharmaceuticals Reports Positive Phase 3 Pivotal Trial Results for EPIDIOLEX® Oral Solution in Patients with Seizures Associated With Tuberous Sclerosis Complex - Achieved primary efficacy measure with both EPIDIOLEX doses as compared to placebo - - Represents the fifth consecutive positive Phase 3 pivotal trial for EPIDIOLEX - - Expect to file sNDA in Q4 2019 -"
04/12/2019 8-K Quarterly results
04/08/2019 8-K Completion of Acquisition or Disposition of Assets
03/18/2019 8-K Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Other Events, Financial State...
Docs: "GW Pharmaceuticals plc Announces the Sale of Priority Review Voucher for $105M"
02/26/2019 8-K Quarterly results
01/07/2019 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "GW Pharmaceuticals plc Corporate Presentation"
11/27/2018 8-K Quarterly results
Docs: "GW Pharmaceuticals plc Reports Fiscal Fourth Quarter and Year-End 2018 Financial Results and Operational Progress - Epidiolex oral solution , first FDA-approved plant-derived cannabinoid medicine launched in the U.S. - - Conference call today at 4:30 p.m. EST - London, UK, Carlsbad, CA, 27 November 2018: GW Pharmaceuticals plc , the world leader in the development and commercialization of cannabinoid prescription medicines, announces financial results for the fourth quarter and year ended 30 September 2018. “We are proud to have recently launched Epidiolex, the first and only FDA-approved plant-derived cannabinoid medicine and a much needed new treatment option for patients with LGS and Dravet syndrome, two of the most difficult-to-treat forms of childhood-onset epilepsy. We are pleased wi..."
11/26/2018 8-K Other Events, Financial Statements and Exhibits
Docs: "GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® oral solution CV in Patients with Dravet Syndrome"
10/05/2018 8-K Quarterly results
10/01/2018 8-K Quarterly results

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy